Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
- PMID: 34777329
- PMCID: PMC8579100
- DOI: 10.3389/fimmu.2021.672255
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
Abstract
We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (ΔDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549rs7767069 SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (per-allele ORMeta=0.83, PMeta=0.000077; PHet=0.61). In addition, we found that each copy of the LRRC55rs717117G allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele ORMeta=0.67, P=0.00058; PHet=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele ORMeta=1.38, P=0.10; PHet=0.45; PInteraction=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the meta-analysis also showed overall and RF-specific associations for the MAFBrs6071980 and CNTN5rs1813443 SNPs with decreased changes in DAS28 (per-allele ORMeta_rs6071980 = 0.85, P=0.0059; PHet=0.63 and ORMeta_rs1813443_RF+=0.81, P=0.0059; PHet=0.69 and ORMeta_rs1813443_RF-=1.00, P=0.99; PHet=0.12; PInteraction=0.032). Mechanistically, we found that subjects carrying the LINC02549rs7767069T allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549rs7767069T/T genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55rs717117G allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated.
Keywords: GWAS; TNF inhibitors; drug response; genetic variant; rheumatoid arthritis.
Copyright © 2021 Sánchez-Maldonado, Cáliz, López-Nevot, Cabrera-Serrano, Moñiz-Díez, Canhão, Ter Horst, Quartuccio, Sorensen, Glintborg, Hetland, Filipescu, Pérez-Pampin, Conesa-Zamora, Swierkot, den Broeder, De Vita, Petersen, Li, Ferrer, Escudero, Netea, Coenen, Andersen, Fonseca, Jurado, Bogunia-Kubik, Collantes and Sainz.
Conflict of interest statement
VA has received compensation for consultancy and for being a member of an advisory board from MSD (Merck) and Janssen. BG received funding for research from AbbVie, Biogen, and Pfizer. MH received funding for research from Abbvie, Biogen, BMS, CellTrion, MSD, Novartis, Orion, Pfizer, Samsung and UCB. JF received unrestricted research grants or acted as a speaker for Abbvie, Ache, Amgen, Biogen, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB. AB has received congress invitations, personal fees and research fees (to the department) from Boehringer, Amgen, Abbvie, Biogen, Cellgene, Pfizer, Novartis, Galapagos, Gilead, Roche, Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Int J Mol Sci. 2022 Feb 21;23(4):2366. doi: 10.3390/ijms23042366. Int J Mol Sci. 2022. PMID: 35216481 Free PMC article. Review.
-
NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium.Sci Rep. 2020 Mar 9;10(1):4316. doi: 10.1038/s41598-020-61331-5. Sci Rep. 2020. PMID: 32152480 Free PMC article.
-
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504. Arthritis Res Ther. 2014. PMID: 24612463 Free PMC article.
-
Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis.PLoS One. 2015 Oct 6;10(10):e0139781. doi: 10.1371/journal.pone.0139781. eCollection 2015. PLoS One. 2015. PMID: 26440629 Free PMC article.
-
Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.Rheumatol Int. 2016 Jun;36(6):837-44. doi: 10.1007/s00296-016-3476-5. Epub 2016 Apr 13. Rheumatol Int. 2016. PMID: 27074847 Review.
Cited by
-
MTHFR c.665C>T and c.1298A>C Polymorphisms in Tailoring Personalized Anti-TNF-α Therapy for Rheumatoid Arthritis.Int J Mol Sci. 2023 Feb 18;24(4):4110. doi: 10.3390/ijms24044110. Int J Mol Sci. 2023. PMID: 36835522 Free PMC article.
-
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.Int J Mol Sci. 2024 Mar 27;25(7):3717. doi: 10.3390/ijms25073717. Int J Mol Sci. 2024. PMID: 38612528 Free PMC article.
-
The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis.Front Pharmacol. 2025 Mar 20;16:1499723. doi: 10.3389/fphar.2025.1499723. eCollection 2025. Front Pharmacol. 2025. PMID: 40183079 Free PMC article.
-
Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Int J Mol Sci. 2022 Feb 21;23(4):2366. doi: 10.3390/ijms23042366. Int J Mol Sci. 2022. PMID: 35216481 Free PMC article. Review.
-
-Omic Approaches and Treatment Response in Rheumatoid Arthritis.Pharmaceutics. 2022 Aug 8;14(8):1648. doi: 10.3390/pharmaceutics14081648. Pharmaceutics. 2022. PMID: 36015273 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous